

Realheart's CEO to Present the Company's Continued Development for Realheart® TAH at the Annual General Meeting on May 28

Västerås, Sweden, May 28, 2026 – Scandinavian Real Heart AB (publ) announces today that CEO Ina Laura Perkins will present the company's current progress, and future plans for Realheart® TAH at the Annual General Meeting on Thursday, May 28, 2026. The meeting will be held at the company's new premises on Hydrovägen in Västerås.

During the presentation, Ina Laura Perkins will provide an update on the company's progress in the field of artificial hearts and the activities underway in preparation for upcoming regulatory and clinical steps.

The recent achievements to be presented are as follows:

- New patent approval in China covering a control method and system configuration
- New patent approval in Australia regarding sensor technology enabling accurate pressure measurements
- Ethics committee approval for chronic in vivo studies in Gothenburg.

"We look forward to welcoming our shareholders to our new offices in Västerås and, at the same time, providing an update on the significant progress being made in the development of Realheart® TAH. We remain focused on achieving the next key milestones in the company's development," says Ina Laura Perkins, CEO of Realheart.

A recording of the presentation will be available shortly, and we will announce when it is ready.

For more information, please contact:

Ina Laura Perkins, CEO

Phone: +46 (0) 70 406 49 21

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, www.skmg.se

About Us

Scandinavian Real Heart AB (publ) is developing the first artificial heart that mimics the shape, function, and blood flow pattern of the human heart. These unique product features provide completely new opportunities to save lives and give patients a good quality of life while waiting for a heart transplant. In the future, artificial hearts may also become an alternative to transplantation for broader groups of patients with severe heart failure. Realheart® TAH (Total Artificial Heart) is now being evaluated in extensive preclinical trials ahead of a first clinical study in patients. The company's shares are traded on Nasdaq Stockholm First North Growth Market. For more information, visit www.realheart.se